A Phase 3 interventional study of Lumateperone 42 mg and Placebo in Schizophrenia, sponsored by Intra-Cellular Therapies, Inc.. Completed at 43 sites in 4 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing lumateperone in Schizophrenia — 3 open to participants now, 3 under way, 2 of them phase 3. lumateperone · Schizophrenia.
Among the 12 studies testing lumateperone in Schizophrenia, this one is the 2nd largest by enrollment, is one of 2 that started in 2021, is one of 5 in phase 3, and was the 8th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →3 of the 12 studies testing lumateperone in Schizophrenia are open now, in 3 countries. Recruiting first, the newest first:
Louisiana State University Health Sciences Center Shreveport · Sites in United States
Ages 18–65
University of Massachusetts, Worcester · Sites in United States
Ages 18–65
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, Serbia
Ages 5–17
By country, each count listing its studies:
lumateperone: first FDA approval 2019 (CAPLYTA). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lumateperone is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 592 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 12 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Intra-Cellular Therapies, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 20th largest by enrollment of the 176 interventional ones that give a count, is one of 3 that started in 2021, is one of 74 in phase 3, and was the 203rd registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing lumateperone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT06174116University of Massachusetts, WorcesterMetabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing lumateperone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5).
The study will be conducted in the following 5 phases:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Schizoaffective disorder, schizophreniform disorder, and other psychotic disorders; Bipolar I or Bipolar II Disorder; Intellectual developmental disorder, delirium, dementia, amnestic and other cognitive disorders; Known or suspected borderline or antisocial personality disorder or other DSM 5 personality disorder of sufficient severity to interfere with participation in this study; Substance use disorder (other than nicotine) within the 3 months prior to Visit 1 of this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lumateperone 42 mg
Drug: Placebo
Lumateperone 42 mg capsules administered orally, once daily.
Matching capsules administered orally, once daily.
Time to First Symptom Relapse During the Double-blind Treatment Phase
Relapse during the DBTP was defined as meeting any one of the following criteria: * Psychiatric hospitalization or need for increased level of psychiatric care due to worsening of the patient's underlying condition; * Increase in PANSS total score by ≥ 30% for patients who scored 50 or higher at randomization or a 10-point or more increase in PANSS total score for patients who scored less than 50 at randomization ; * Increase in the Visit 14 CGI-S score by 2 or more points; * Deliberate self-injury or aggressive/violent behavior; * Any suicidal ideation or homicidal ideation; * Score of greater than 4 on 1 or more of the following PANSS items: P1, P2, P3, P6, P7, G8 or G14
Time frame: Number of days from the randomization date to the first relapse date up to 26 weeks.
| Milestone | Lumateperone 42 mg Open-label Treatment Phase | Lumateperone 42 mg - Double-blind Treatment Phase | Placebo - Double-blind Treatment Phase |
|---|---|---|---|
| Started | 592 | 0 | 0 |
| Completed | 228 | 0 | 0 |
| Not completed | 364 | 0 | 0 |
| Withdrew: Adverse event | 54 | 0 | 0 |
| Withdrew: Lack of efficacy | 122 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 46 | 0 | 0 |
| Withdrew: Protocol violation | 35 | 0 | 0 |
| Withdrew: Withdrawal by subject | 104 | 0 | 0 |
| Withdrew: Inability to identify a caregiver and patient incarceration | 2 | 0 | 0 |
| Milestone | Lumateperone 42 mg Open-label Treatment Phase | Lumateperone 42 mg - Double-blind Treatment Phase | Placebo - Double-blind Treatment Phase |
|---|---|---|---|
| Started | 0 | 114 | 114 |
| Completed | 0 | 94 | 98 |
| Not completed | 0 | 20 | 16 |
| Withdrew: Adverse event | 0 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 4 | 3 |
| Withdrew: Pregnancy | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 9 | 8 |
Relapse during the DBTP was defined as meeting any one of the following criteria: * Psychiatric hospitalization or need for increased level of psychiatric care due to worsening of the patient's underlying condition; * Increase in PANSS total score by ≥ 30% for patients who scored 50 or higher at randomization or a 10-point or more increase in PANSS total score for patients who scored less than 50 at randomization ; * Increase in the Visit 14 CGI-S score by 2 or more points; * Deliberate self-injury or aggressive/violent behavior; * Any suicidal ideation or homicidal ideation; * Score of greater than 4 on 1 or more of the following PANSS items: P1, P2, P3, P6, P7, G8 or G14
| days | Lumateperone 42 mg | Placebo |
|---|---|---|
| Time to First Symptom Relapse During the Double-blind Treatment Phase | NA (NA to NA) | NA (NA to NA) |
Collected over From signing ICF until end of study procedures (up to 47 weeks), including 18 weeks of open-label treatment and up to 26 weeks of double-blind treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lumateperone 42 mg Open-label Treatment Phase | 1/592 (0.2%) | 23/592 (3.9%) | 85/592 (14.4%) |
| Lumateperone 42 mg Double-blind Treatment Phase | 0/110 (0%) | 1/110 (0.9%) | 9/110 (8.2%) |
| Placebo Double-blind Treatment Phase | 0/114 (0%) | 7/114 (6.1%) | 10/114 (8.8%) |
| Event | Lumateperone 42 mg Open-label Treatment Phase | Lumateperone 42 mg Double-blind Treatment Phase | Placebo Double-blind Treatment Phase |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 9/592 | 1/110 | 6/114 |
| Psychotic DisorderPsychiatric disorders | 7/592 | 0/110 | 0/114 |
| Muscle InjuryInjury, poisoning and procedural complications | 0/592 | 0/110 | 1/114 |
| Acute Kidney InjuryRenal and urinary disorders | 0/592 | 0/110 | 1/114 |
| Suicidal IdeationPsychiatric disorders | 3/592 | 0/110 | 0/114 |
| Intestinal ObstructionGastrointestinal disorders | 1/592 | 0/110 | 0/114 |
| Covid-19Infections and infestations | 1/592 | 0/110 | 0/114 |
| Acute PsychosisPsychiatric disorders | 1/592 | 0/110 | 0/114 |
| Completed SuicidePsychiatric disorders | 1/592 | 0/110 | 0/114 |
| Event | Lumateperone 42 mg Open-label Treatment Phase | Lumateperone 42 mg Double-blind Treatment Phase | Placebo Double-blind Treatment Phase |
|---|---|---|---|
| HeadacheNervous system disorders | 78/592 | 9/110 | 4/114 |
| SchizophreniaPsychiatric disorders | 9/592 | 0/110 | 6/114 |
| Age, Continuous(years) | Lumateperone 42 mg Open-label Treatment Phase |
|---|---|
| Mean | 42.5 ± 10.80 |
| Sex: Female, Male(Participants) | Lumateperone 42 mg Open-label Treatment Phase |
|---|---|
| Female | 178 |
| Male | 414 |
| Race/Ethnicity, Customized(Participants) | Lumateperone 42 mg Open-label Treatment Phase |
|---|---|
| White | 299 |
| Black or African American | 277 |
| Asian | 8 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Other | 2 |
| Multiple | 5 |
| Region of Enrollment(participants) | Lumateperone 42 mg Open-label Treatment Phase |
|---|---|
| United States | 382 |
| Poland | 24 |
| Bulgaria | 115 |
| Serbia | 71 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2021 to primary completion in Jul 2024, 36 months.
Results were first posted in Oct 2026, 2 years 2 months after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 36 months is above that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumateperone
Intra-Cellular Therapies, Inc. →